Last updated: May 20, 2026
Ketoprofen is an established NSAID with a mature global market and no single “blockbuster” branded monopoly. Clinical activity is now dominated by (1) formulation and delivery-system optimization (topical gels, patches, extended-release oral), (2) comparative efficacy and safety studies versus other NSAIDs, and (3) pharmacokinetic or bioequivalence work supporting generic and “authorized generic” launches.
How many clinical trials are ongoing for ketoprofen, and what are they testing?
Short answer: Active studies cluster around localized pain indications (osteoarthritis, musculoskeletal pain) and delivery improvements (topical absorption, controlled release, combination products). Many newer trials are not “new drug” discovery but clinical evidence packages for formulation differentiation and market entry.
What trial types dominate ketoprofen studies (latest patterns)
Most recent ketoprofen trial registrations fall into these buckets:
- Topical ketoprofen: gel/cream efficacy and tolerability for acute sprains, tendon disorders, and osteoarthritis flares.
- Oral ketoprofen: comparative dosing regimens, safety in target populations, and bioequivalence for generics.
- Controlled-release / fast-acting: formulation performance, onset of pain relief, and adherence-focused regimens.
- Combination products: co-formulated NSAID approaches (where permitted), often compared against ketoprofen alone.
Which indications show up most often
Commonly targeted:
- Osteoarthritis-related pain (knee OA, hand OA)
- Acute musculoskeletal injury (sprain, strain)
- Low back pain and periarticular pain syndromes
- Post-operative or procedure-associated pain in smaller studies (often short duration)
What endpoints are used
- Pain score reductions (VAS/NRS) over short time windows
- Functional scores for OA (mobility and daily activity measures)
- Safety endpoints: GI adverse events, renal labs (in oral studies), skin reactions (topical)
What is the most recent ketoprofen clinical trial data on efficacy and safety?
Short answer: The clinical evidence base continues to support ketoprofen as a standard NSAID with efficacy comparable to other NSAIDs for localized and musculoskeletal pain, with safety consistent with NSAID class risks.
What efficacy signals are consistent across modern studies
- Faster or comparable pain reduction versus placebo across typical NSAID endpoints.
- Topical formulations generally show benefit in local pain with reduced systemic exposure signals compared with oral.
- Comparative trials frequently benchmark against diclofenac, ibuprofen, naproxen, and other NSAIDs.
What safety findings are most consistently reported
- Oral ketoprofen: GI events remain the primary class concern; renal monitoring is common in protocolized studies.
- Topical ketoprofen: dermatitis and local irritation are the main safety signals.
- Overall discontinuation rates typically track with NSAID comparators.
How do study results affect product positioning?
Because ketoprofen is mature, modern clinical evidence is used for:
- label expansion in specific geographies
- formulation differentiation for topical vs oral
- clinician confidence for switching within the NSAID class
What is ketoprofen’s current FDA and global regulatory status for each dosage form?
Short answer: Ketoprofen remains approved as an NSAID across multiple countries in topical and oral forms, but the exact product status and labeling vary by brand and geography.
United States
In the US, ketoprofen is typically associated with established OTC or Rx NSAID products depending on formulation/strength and historical labeling. Competitive access in the US is largely shaped by Orange Book listing status for specific NDCs and patent expirations tied to particular strengths and dosage forms.
Europe and other major markets
Across EU and similar markets, ketoprofen products are generally positioned as:
- topical pain relief
- oral NSAID pain relief
- with dosing and safety language aligned with NSAID class standards
What is the Orange Book status of ketoprofen and which patents limit generic entry?
Short answer: Patent and exclusivity limitations are product-specific (by NDC, dosage form, and route). For ketoprofen, generic entry is generally enabled once listed patents and any exclusivity periods for that specific product configuration expire.
How to interpret “Orange Book status” for a mature NSAID
- Mature actives tend to have thin current exclusivity but can still have:
- formulation-specific patents (especially for topical gels/patches)
- method-of-use claims tied to labeling
- manufacturing process claims for specific dosage technologies
Practical implication for market participants
The main barriers are usually:
- remaining listed patents for particular ketoprofen product configurations
- product-specific data exclusivity where applicable to formulation changes (jurisdiction-dependent)
Which companies sell ketoprofen globally and how does the competitive landscape look?
Short answer: The competitive landscape is fragmented: multiple generic manufacturers supply oral and topical ketoprofen, while a small number of branded legacy products persist in select markets.
Market structure by channel
- Retail pharmacy and OTC: topical and selected oral strengths dominate volume in many markets.
- Hospital/clinic: oral dosing for short-term acute pain; topical for localized musculoskeletal pain when systemic risk management is preferred.
Competitive set
Ketoprofen competes against:
- diclofenac (gel and tablets)
- ibuprofen
- naproxen
- ketorolac (more surgery-focused and short-course due to safety framing)
How big is the ketoprofen market today and where is growth coming from?
Short answer: Growth is moderate and largely driven by:
- continued demand for musculoskeletal pain treatments
- substitution within the NSAID class
- incremental growth of topical OTC use in target geographies
Demand drivers
- aging populations and osteoarthritis prevalence
- increase in outpatient management of sprains and strains
- OTC topical switching trends
Constraints
- NSAID class safety risk, especially oral GI and renal adverse event concerns
- regulatory tightening around oral NSAID labeling and risk-management messaging
- clinician preference shifts toward selective COX-2 or non-NSAID modalities in some countries
What are the key pricing and reimbursement dynamics for ketoprofen?
Short answer: Pricing is shaped by generic competition and form-specific value perception. Topical ketoprofen often holds better relative pricing per dose than older oral generics once OTC adoption is established, but payer coverage varies.
Reimbursement patterns
- Many markets reimburse topical pain NSAIDs at low tiers or through OTC channels.
- Oral NSAID reimbursement can be more variable based on safety wording, risk categories, and local prescribing guidelines.
How competition affects gross-to-net
- rapid NDC price erosion after generic launch
- margin compression as supply expands
- promotional spending in OTC channels where permitted
Ketoprofen market projection: what revenue range is realistic over the next 5 years?
Short answer: Near-term growth is likely low-to-mid single digits globally, with upside in topical segments and mature-market OTC demand. The forecast depends on formulation mix and geography, but absent a new “breakthrough” drug event, ketoprofen behaves like a mature NSAID with steady volume replacement economics.
5-year base-case projection (structure)
Because ketoprofen is mature and generic-heavy, a realistic projection framework is:
- Unit growth: low single-digit growth driven by population and pain prevalence
- Price decline: offset by shift to topical and OTC where pricing stabilizes relative to oral
- Share shifts: competitive switching between NSAIDs
Scenario ranges
- Base case: low-to-mid single-digit CAGR driven by topical mix and continued generic volume supply
- Downside: faster price erosion and substitution to other NSAIDs with stronger clinical positioning
- Upside: sustained topical growth in markets with favorable OTC access and physician preference for reduced systemic NSAID risk
What generic entry risks exist for ketoprofen, and where are barriers likely?
Short answer: Generic risks are mostly tied to product-specific patent/Orange Book status for particular dosage forms and strengths. Manufacturing barriers are typically non-scientific and more compliance and quality-system driven.
Where barriers show up in practice
- topical formulations with specific rheology or delivery claims may have formulation IP remnants in some jurisdictions
- method-of-use or dosing regimen claims can affect carve-outs in certain litigation contexts
- regulatory submission packages can be delayed by data requirements for changed excipients or manufacturing sites
What makes a ketoprofen product “launch-resistant”
- active patents listed against specific NDCs
- local regulatory data requirements for formulation changes
- market authorization delays (CMC changes, site transfers)
How does ketoprofen compare with diclofenac and ibuprofen for clinical and market outcomes?
Short answer: Clinically, ketoprofen sits in the NSAID equivalency zone for many musculoskeletal pain use cases. Market outcomes depend more on product accessibility, topical brand legacy, and competitive pricing than on unique pharmacology.
Topical comparison
- Ketoprofen topical is competing with diclofenac gels, which often have stronger brand familiarity in some markets.
- Pricing and OTC accessibility drive share.
- Safety messaging is broadly NSAID-consistent; local irritation profiles differ but are typically manageable.
Oral comparison
- Ibuprofen and naproxen benefit from extensive generic presence and payer familiarity.
- Ketoprofen oral uptake is typically strongest where established prescribing patterns already exist.
What ketoprofen formulation innovations are in the pipeline?
Short answer: The incremental innovation focus continues to be:
- topical absorption and skin tolerability refinement
- controlled release oral approaches
- combination formulations where approved
- excipient optimization to support stability and bioavailability for generics
Why formulation matters commercially
For ketoprofen, differentiation is more feasible in:
- topical performance (local delivery)
- patient adherence (dosing frequency)
- tolerability positioning
What ketoprofen patent litigation matters to market entry?
Short answer: Patent litigation risk remains mostly product- and NDC-specific rather than active-substance-wide for ketoprofen. The practical question is whether any formulation or method-of-use patents remain listed for the specific dosage form being targeted for generic entry.
Litigation affects
- timing of ANDA/marketing approvals
- launch design (label carve-outs or dosing adjustments)
- settlement terms that can delay entry even after clinical data packages are ready
Key Takeaways
- Ketoprofen clinical activity is now dominated by formulation, delivery, and comparative NSAID studies rather than novel mechanism research.
- Efficacy and safety outcomes align with NSAID class expectations: pain reduction benefits with GI/renal concerns for oral and local irritation for topical.
- Regulatory status is mature; market access depends on product-specific Orange Book listings and any remaining formulation or method-of-use IP for particular dosage forms.
- Global market growth is likely low-to-mid single digits over the next five years, driven mainly by topical mix and OTC access, while oral faces continued price erosion from generic competition.
FAQs
- What are the most common ketoprofen trial endpoints for topical gel studies?
- Do topical ketoprofen trials show lower systemic exposure than oral ketoprofen?
- Which ketoprofen strengths and routes typically face the longest generic approval timelines in the US?
- How do ketoprofen and diclofenac compare in real-world musculoskeletal pain management?
- What formulation attributes most influence topical ketoprofen bioavailability and tolerability?
References (APA)
- ClinicalTrials.gov. (n.d.). Ketoprofen studies. https://clinicaltrials.gov/
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA and Orange Book resources. https://www.accessdata.fda.gov/scripts/cder/daf/ and https://www.accessdata.fda.gov/scripts/cder/ob/
